Criteria and regulatory considerations for the conditional approval of innovative antitumor drugs in China: from the perspective of clinical reviewers.
作者信息
Zou Limin, Qi Yueli, Jiang Yongling, Tang Ling, Du Yu, Zhao Boyuan, Sun Yanzhe, Xiang Meiyi, Ma Jun, Yang Zhimin
机构信息
Office of Clinical Evaluation 1, Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, P. R. China.
Office of Management and Communication, Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, P. R. China.
出版信息
Cancer Commun (Lond). 2023 Feb;43(2):171-176. doi: 10.1002/cac2.12400. Epub 2023 Jan 22.
Abstract
摘要
Zotero 插件